---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036977"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2026-08-11T11:00:24+00:00"
generated_at: "2026-08-11T11:05:43.292421+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events

## Summary
- First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.
- No adverse events reported during treatment; company cites case as supporting further evaluation.
- PLICID is an ASI-designed galectin antagonist; Bioxytran plans a larger clinical study.
- Company acknowledges single-patient observations are not sufficient to establish safety or efficacy.

## SEC filing metadata
- accession: 0001493152-26-036977
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2026-08-11T11:00:24+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/0001493152-26-036977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036977
- JSON: https://secwatch.observer/filing/0001493152-26-036977.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.